Alpine Immune Sciences (FRA:34LA) Short Percentage of Float

View and export this data going back to 2015. Start your Free Trial

What is Alpine Immune Sciences Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Alpine Immune Sciences's Short Percentage of Float

For the Biotechnology subindustry, Alpine Immune Sciences's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alpine Immune Sciences's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpine Immune Sciences's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Alpine Immune Sciences's Short Percentage of Float falls into.

Alpine Immune Sciences (FRA:34LA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpine Immune Sciences Inc (FRA:34LA) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

ALPN:USA 34LA:Germany

Address

188 East Blaine Street, Suite 200, Seattle, WA, USA, 98102

Website

https://www.alpineimmunesciences.com

Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Alpine Immune Sciences (FRA:34LA) Headlines

No Headlines